Literature DB >> 33407930

Dysfunction in nonsense-mediated decay, protein homeostasis, mitochondrial function, and brain connectivity in ALS-FUS mice with cognitive deficits.

Wan Yun Ho1, Ira Agrawal1, Sheue-Houy Tyan2, Emma Sanford1, Wei-Tang Chang3,4, Kenneth Lim1,5, Jolynn Ong1, Bernice Siu Yan Tan1, Aung Aung Kywe Moe6,7, Regina Yu6,7, Peiyan Wong8,9, Greg Tucker-Kellogg5,10, Edward Koo3,11, Kai-Hsiang Chuang3,6,7, Shuo-Chien Ling12,13,14.   

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent two ends of the same disease spectrum of adult-onset neurodegenerative diseases that affect the motor and cognitive functions, respectively. Multiple common genetic loci such as fused in sarcoma (FUS) have been identified to play a role in ALS and FTD etiology. Current studies indicate that FUS mutations incur gain-of-toxic functions to drive ALS pathogenesis. However, how the disease-linked mutations of FUS affect cognition remains elusive. Using a mouse model expressing an ALS-linked human FUS mutation (R514G-FUS) that mimics endogenous expression patterns, we found that FUS proteins showed an age-dependent accumulation of FUS proteins despite the downregulation of mouse FUS mRNA by the R514G-FUS protein during aging. Furthermore, these mice developed cognitive deficits accompanied by a reduction in spine density and long-term potentiation (LTP) within the hippocampus. At the physiological expression level, mutant FUS is distributed in the nucleus and cytosol without apparent FUS aggregates or nuclear envelope defects. Unbiased transcriptomic analysis revealed a deregulation of genes that cluster in pathways involved in nonsense-mediated decay, protein homeostasis, and mitochondrial functions. Furthermore, the use of in vivo functional imaging demonstrated widespread reduction in cortical volumes but enhanced functional connectivity between hippocampus, basal ganglia and neocortex in R514G-FUS mice. Hence, our findings suggest that disease-linked mutation in FUS may lead to changes in proteostasis and mitochondrial dysfunction that in turn affect brain structure and connectivity resulting in cognitive deficits.

Entities:  

Keywords:  Amyotrophic lateral sclerosis (ALS); Auto-regulation; Brain connectivity; FUS (fused in sarcoma); Frontotemporal dementia (FTD); Functional magnetic resonance imaging (fMRI); Nonsense-mediated decay (NMD); Oxidation phosphorylation (OXPHOS); Protein homeostasis

Year:  2021        PMID: 33407930      PMCID: PMC7789430          DOI: 10.1186/s40478-020-01111-4

Source DB:  PubMed          Journal:  Acta Neuropathol Commun        ISSN: 2051-5960            Impact factor:   7.801


  87 in total

1.  SMG7 is a 14-3-3-like adaptor in the nonsense-mediated mRNA decay pathway.

Authors:  Noemi Fukuhara; Judith Ebert; Leonie Unterholzner; Doris Lindner; Elisa Izaurralde; Elena Conti
Journal:  Mol Cell       Date:  2005-02-18       Impact factor: 17.970

2.  Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.

Authors:  Xue Hua; Alex D Leow; Neelroop Parikshak; Suh Lee; Ming-Chang Chiang; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2008-07-22       Impact factor: 6.556

3.  Robust automatic rodent brain extraction using 3-D pulse-coupled neural networks (PCNN).

Authors:  Nigel Chou; Jiarong Wu; Jordan Bai Bingren; Anqi Qiu; Kai-Hsiang Chuang
Journal:  IEEE Trans Image Process       Date:  2011-03-14       Impact factor: 10.856

Review 4.  The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.

Authors:  Oliver D King; Aaron D Gitler; James Shorter
Journal:  Brain Res       Date:  2012-01-21       Impact factor: 3.252

5.  ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects.

Authors:  Haiyan Qiu; Sebum Lee; Yulei Shang; Wen-Yuan Wang; Kin Fai Au; Sherry Kamiya; Sami J Barmada; Steven Finkbeiner; Hansen Lui; Caitlin E Carlton; Amy A Tang; Michael C Oldham; Hejia Wang; James Shorter; Anthony J Filiano; Erik D Roberson; Warren G Tourtellotte; Bin Chen; Li-Huei Tsai; Eric J Huang
Journal:  J Clin Invest       Date:  2014-02-10       Impact factor: 14.808

6.  In vivo stress granule misprocessing evidenced in a FUS knock-in ALS mouse model.

Authors:  Xue Zhang; Fengchao Wang; Yi Hu; Runze Chen; Dawei Meng; Liang Guo; Hailong Lv; Jisong Guan; Yichang Jia
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501

7.  Minor intron splicing is regulated by FUS and affected by ALS-associated FUS mutants.

Authors:  Stefan Reber; Jolanda Stettler; Giuseppe Filosa; Martino Colombo; Daniel Jutzi; Silvia C Lenzken; Christoph Schweingruber; Rémy Bruggmann; Angela Bachi; Silvia Ml Barabino; Oliver Mühlemann; Marc-David Ruepp
Journal:  EMBO J       Date:  2016-06-01       Impact factor: 11.598

8.  Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels.

Authors:  Masato Kato; Tina W Han; Shanhai Xie; Kevin Shi; Xinlin Du; Leeju C Wu; Hamid Mirzaei; Elizabeth J Goldsmith; Jamie Longgood; Jimin Pei; Nick V Grishin; Douglas E Frantz; Jay W Schneider; She Chen; Lin Li; Michael R Sawaya; David Eisenberg; Robert Tycko; Steven L McKnight
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

9.  Mutant FUS and ELAVL4 (HuD) Aberrant Crosstalk in Amyotrophic Lateral Sclerosis.

Authors:  Riccardo De Santis; Vincenzo Alfano; Valeria de Turris; Alessio Colantoni; Laura Santini; Maria Giovanna Garone; Giuseppe Antonacci; Giovanna Peruzzi; Emma Sudria-Lopez; Emanuel Wyler; Jasper J Anink; Eleonora Aronica; Markus Landthaler; R Jeroen Pasterkamp; Irene Bozzoni; Alessandro Rosa
Journal:  Cell Rep       Date:  2019-06-25       Impact factor: 9.423

10.  ALS/FTD-associated protein FUS induces mitochondrial dysfunction by preferentially sequestering respiratory chain complex mRNAs.

Authors:  Yueh-Lin Tsai; Tristan H Coady; Lei Lu; Dinghai Zheng; Isabel Alland; Bin Tian; Neil A Shneider; James L Manley
Journal:  Genes Dev       Date:  2020-05-07       Impact factor: 11.361

View more
  5 in total

Review 1.  The Interplay of RNA Binding Proteins, Oxidative Stress and Mitochondrial Dysfunction in ALS.

Authors:  Jasmine Harley; Benjamin E Clarke; Rickie Patani
Journal:  Antioxidants (Basel)       Date:  2021-04-02

2.  A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics.

Authors:  Gaël Nicolas; Myriam Sévigny; François Lecoquierre; Florent Marguet; Andréanne Deschênes; Maria Carment Del Pelaez; Sébastien Feuillette; Anaïs Audebrand; Magalie Lecourtois; Stéphane Rousseau; Anne-Claire Richard; Kévin Cassinari; Vincent Deramecourt; Charles Duyckaerts; Anne Boland; Jean-François Deleuze; Vincent Meyer; Jordi Clarimon Echavarria; Ellen Gelpi; Haruhiko Akiyama; Masato Hasegawa; Ito Kawakami; Tsz H Wong; Jeroen G J Van Rooij; John C Van Swieten; Dominique Campion; Paul A Dutchak; David Wallon; Flavie Lavoie-Cardinal; Annie Laquerrière; Anne Rovelet-Lecrux; Chantelle F Sephton
Journal:  Acta Neuropathol Commun       Date:  2022-02-12       Impact factor: 7.801

Review 3.  Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease.

Authors:  Pauline A Gelon; Paul A Dutchak; Chantelle F Sephton
Journal:  Front Mol Neurosci       Date:  2022-10-03       Impact factor: 6.261

4.  Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients.

Authors:  David Bayer; Stefano Antonucci; Hans-Peter Müller; Rami Saad; Luc Dupuis; Volker Rasche; Tobias M Böckers; Albert C Ludolph; Jan Kassubek; Francesco Roselli
Journal:  Transl Neurodegener       Date:  2021-05-31       Impact factor: 8.014

5.  Reactive astrocytes in ALS display diminished intron retention.

Authors:  Oliver J Ziff; Doaa M Taha; Hamish Crerar; Benjamin E Clarke; Anob M Chakrabarti; Gavin Kelly; Jacob Neeves; Giulia E Tyzack; Nicholas M Luscombe; Rickie Patani
Journal:  Nucleic Acids Res       Date:  2021-04-06       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.